|
|
 |
|
Viewing report
|
|
|
|
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
Decision Resources, Inc., Sep 2009, Pages: 35
In this report, we feature a commentary by Alex M. Brill, CEO of Matrix Global Advisors and a research fellow at the American Enterprise Institute, who testifi ed before the U.S. House Judiciary Committee’s Subcommittee on Courts and Competition on July 14, 2009, regarding data exclusivity for biosimilars. We also provide insights from an interviewed health policy lobbyist who is active in government affairs in Washington, D.C. He spoke on background concerning recent negotiations on healthcare reform, authorized generics, and reverse payment deals. Kevin E. Noonan, J.D., Ph.D., a partner at McDonnell Boehnen Hulbert & Berghoff, gives his insights on patent reform and healthcare reform.
Customers who bought this item also bought
Biosimilars: A Viable Market - But When?
Biosimilars: Beyond the first product wave
Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment
Biosimilars (2009 - 2014)
Meeting the Challenges of Manufacturing Biosimilars
Generics Series: Authorized Generics Analysis
Biosimilars Series: Forecast Analysis
Biosimilars and Biobetters: Positioning for a New Market
Biosimilars Series: Strategic Issues - Potential Remains Uncertain
Biosimilars Series: Regulatory and development issues hurdles exist but are surmountable
Biosimilars - Evolution or Revolution?
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
|
|
|
|
